Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

TARA-002

Other · Immune activation · developed by Protara Therapeutics

Phase 3 Most advanced trial
TARA Developer
1 Registered trials

What is TARA-002?

TARA-002 is a lyophilized preparation of killed, penicillin-treated group A Streptococcus pyogenes (Su strain) given intravesically as an immunostimulant. It is studied in non-muscle invasive bladder cancer, including bladder carcinoma in situ.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Mechanism
Immune activation
Pathways
innate and adaptive immune activation, IL-6, IL-8, IL-12, IFN-gamma, TNF-alpha and VEGF production
Therapy area
Oncology
Developer
Protara Therapeutics (TARA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
2F42BH7X2L

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07480356 Phase 3 Bladder (Urothelial, Transitional Cell) Cancer Recruiting TARA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Bladder (Urothelial, Transitional Cell) CancerNon-muscle Invasive Bladder Cancer With Carcinoma in SituNon-Muscle Invasive Bladder Carcinoma

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the TARA page.

Follow TARA, the company behind TARA-002

See TARA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TARA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.